...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >Activation of α7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents A?-mediated inhibition of LTP in the rat hippocampus
【24h】

Activation of α7 nicotinic acetylcholine receptors persistently enhances hippocampal synaptic transmission and prevents A?-mediated inhibition of LTP in the rat hippocampus

机译:α7烟碱乙酰胆碱受体的激活持续增强海马突触传递并防止Aβ介导的大鼠海马LTP抑制

获取原文
获取原文并翻译 | 示例
           

摘要

Nicotinic acetylcholine receptors mediate fast cholinergic modulation of glutamatergic transmission and synaptic plasticity. Here we investigated the effects of subtype selective activation of the α7 nicotinic acetylcholine receptors on hippocampal transmission and the inhibition of synaptic long-term potentiation by the Alzheimer's disease associated amyloid ?-protein (A?). The α7 nicotinic acetylcholine receptor agonist "compound A" ((R)-N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl))thiophene-2- carboxamide) induced a rapid-onset persistent enhancement of synaptic transmission in the dentate gyrus in vitro. Consistent with a requirement for activation of α7 nicotinic acetylcholine receptors, the type II α7-selective positive allosteric modulator PheTQS ((3aR, 4S, 9bS)-4-(4-methylphenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c] quinoline-8-sulfonamide) potentiated, and the antagonist methyllycaconitine (MLA) prevented the persistent enhancement. Systemic injection of the agonist also induced a similar MLA-sensitive persistent enhancement of synaptic transmission in the CA1 area in vivo. Remarkably, although compound A did not affect control long-term potentiation (LTP) in vitro, it prevented the inhibition of LTP by A?1-42 and this effect was inhibited by MLA. These findings strongly indicate that activation of α7 nicotinic acetylcholine receptors is sufficient to persistently enhance hippocampal synaptic transmission and to overcome the inhibition of LTP by A?.
机译:烟碱乙酰胆碱受体介导谷氨酸能传递和突触可塑性的快速胆碱能调节。在这里,我们研究了α7烟碱型乙酰胆碱受体亚型选择性激活对海马传播的影响以及阿尔茨海默氏病相关淀粉样β蛋白(Aβ)对突触长期增强的抑制作用。 α7烟碱型乙酰胆碱受体激动剂“化合物A”((R)-N-(1-氮杂双环[2.2.2] oct-3-yl)(5-(2-吡啶基))噻吩-2-羧酰胺)诱导迅速齿状回体外突触持续增强突触传递。 II型α7选择性正构构调节剂PheTQS((3aR,4S,9bS)-4-(4-甲基苯基)-3a,4,5,9b-tetrahydro-3H与激活α7烟碱乙酰胆碱受体的要求一致-环戊[[c]喹啉-8-磺酰胺)增强,而拮抗剂甲基卡可宁(MLA)阻止了持续增强。激动剂的全身注射还在体内CA1区域中诱导了类似的MLA敏感的突触传递的持续增强。值得注意的是,尽管化合物A在体外不影响对照长期增强(LTP),但它阻止了Aβ1-42对LTP的抑制作用,而这种作用被MLA抑制了。这些发现强烈表明,α7烟碱乙酰胆碱受体的活化足以持续增强海马突触传递并克服Aβ对LTP的抑制作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号